Open AccessPostlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006–2017
Author(s) -
Reddy Neha,
Viswam Subeesh,
Elsa Beulah,
Gouri Nair,
Eswaran Maheswari
Publication year - 2020
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/picr.picr_140_18
Subject(s) - human papillomavirus vaccine , adverse event reporting system , virology , human papillomavirus , medicine , event (particle physics) , adverse effect , gardasil , cervical cancer , cancer , physics , quantum mechanics
The United States Food and Drug Administration (FDA) has licensed three HPV (Human papilloma virus) vaccines. The centers for disease control and prevention (CDC) and advisory committee on immunization practices (ACIP) recommends routine HPV vaccination at age 11 or 12 years. This study aimed to summarize and characterize adverse events following HPV vaccination reported to VAERS database from July 2006 to May 2017.